AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2024
Aug 14, 2024
33483_dirs_2024-08-14_23e6fe6f-b94a-4160-813b-021fb668bee1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-08-12
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-12 | Common Stock | P | 8016 | $12.7205 | Acquired | 11509 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4379899 | Direct |
| Common Stock | 1927630 | Indirect |
Footnotes
F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $12.48 to $13.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.